217 results
Page 5 of 11
8-K
EX-99.1
5zc3qi54tqywgpzkmw
9 Nov 10
Results of Operations and Financial Condition
12:00am
CORRESP
48hdwawv 0azp
8 Nov 10
Correspondence with SEC
12:00am
8-K
EX-99.1
ccl3b13
21 Oct 10
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer
12:00am
8-K
ti6yy
21 Oct 10
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer
12:00am
8-K
EX-99.1
mvx 6ned2
13 Oct 10
Entry into a Material Definitive Agreement
12:00am
424B5
mdtkrpici08 9kd3cfuo
13 Oct 10
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
wcmt2b27dvf
4 Aug 10
Discovery Labs Provides Business Update and Reports Second Quarter 2010 Financial Results
12:00am
424B5
izum0d3 ub
18 Jun 10
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
h19dczy
17 Jun 10
Discovery Labs Prices $10.0 Million Public Offering of
12:00am
424B5
y6b3xs7z
16 Jun 10
Prospectus supplement for primary offering
12:00am
424B3
qqahd
15 Jun 10
Prospectus supplement
12:00am
8-K
EX-99.1
m1ih651qus9ukytr2bo
14 Jun 10
Discovery Labs Secures $35 Million Committed Equity Financing Facility
12:00am
8-K
EX-99.1
uzt63nvntvgzfsgvx
9 Jun 10
Discovery Labs Reports Preliminary Results from Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure
12:00am
8-K
EX-99.1
g277f1 tqveg
9 Jun 10
Discovery Labs Receives FDA Guidance Regarding Preclinical Program to
12:00am
8-K
EX-99.1
uu4mavmpa
4 Jun 10
Discovery Labs Announces Listing Transfer to NASDAQ Capital Market
12:00am
8-K
EX-99.1
aa016n19xg39qii75w
21 May 10
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval
12:00am